Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Linda Englander, SPHR

Advertisement

Articles by Linda Englander, SPHR

Why We�re Not Reaching Women With Metastatic Breast Cancer and How We Can Change That

ByLinda Englander, SPHR
September 22nd 2008

Breast Cancer Network of Strength is always looking for different ways to meet the needs of women with breast cancer.

Advertisement

Latest Updated Articles

  • Why We�re Not Reaching Women With Metastatic Breast Cancer and How We Can Change That
    Why We�re Not Reaching Women With Metastatic Breast Cancer and How We Can Change That

    September 22nd 2008



Advertisement
Advertisement

Trending on OncLive

1

Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management

2

Dr Akhade on Building the Evidence Base for Low-Dose Immunotherapy

3

FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

4

EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options

5

Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us